Recurrent staphylococcal infections: Metabolism matters

Staphylococcal metabolic adaptation during infection can promote recurrence.

Published in Microbiology

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Staphylococcus aureus is a formidable pathogen capable of causing infections ranging from acute to subacute and chronic. While the role of virulence factors including toxins in establishing acute infection has been thoroughly investigated, how S. aureus adapts to cause chronic infection is still unclear.

Small colony variants (SCVs) are frequently isolated from persistent infections despite their notorious lack of virulence determinants1. They often harbour inactivating mutations in genes associated with the production of terminal electron transport chain components resulting in the upregulation of glycolysis to produce ATP2. Our lab, amongst others, has previously demonstrated the immunological consequences associated with microbial induction of host metabolism particularly glycolysis by live S. aureus3. This led us to postulate that the metabolic response during an SCV infection would promote their recurrence.

To address our hypothesis, we turned to Seahorse extracellular flux assays and metabolomics. The Seahorse analyses showed that our prototypic SCV stimulated glycolysis in human monocytes whereas metabolomics revealed major differences in the metabolome profile of WT versus SCV-infected human peripheral blood mononuclear cells (PBMCs) including lower levels of fumarate during SCV infection.

Recent findings showed that WT S. aureus activates trained immunity in the skin, a response that is conferred by metabolic changes within macrophages and promotes secondary staphylococcal protection4-6. Given the distinct metabolic signature observed during SCV infection of PBMCs, we postulated that SCVs fail to stimulate trained immunity via metabolic adaptation, promoting recurrence. We found that SCVs indeed failed to induce memory in the skin of mice and questioned whether this was due to the lower levels of fumarate observed during in vitro and in vivo SCV infection. Interestingly, we found that the SCVs increase the expression of fumC, which encodes the enzyme that degrades fumarate and that an SCV prototype lacking fumC stimulated memory unlike its counterpart that overexpresses fumC, confirming the role of fumarate in stimulating secondary staphylococcal protection.

References:

1          Proctor, R. A. et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4, 295-305, (2006).

2          Kriegeskorte, A. et al. Staphylococcus aureus small colony variants show common metabolic features in central metabolism irrespective of the underlying auxotrophism. Frontiers in cellular and infection microbiology 4, 141, (2014).

3          Wickersham, M. et al. Metabolic Stress Drives Keratinocyte Defenses against Staphylococcus aureus Infection. Cell Rep 18, 2742-2751, (2017).

4          Chan, L. C. et al. Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus. Infection and immunity 85, (2017).

5          Chan, L. C. et al. Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory. Proc Natl Acad Sci U S A, (2018).

6          Arts, R. J. et al. Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metab 24, 807-819, (2016).

 


Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Microbiology
Life Sciences > Biological Sciences > Microbiology

Related Collections

With collections, you can get published faster and increase your visibility.

Progress towards the Sustainable Development Goals

The year 2023 marks the mid-point of the 15-year period envisaged to achieve the Sustainable Development Goals, targets for global development adopted in September 2015 by all United Nations Member States.

Publishing Model: Hybrid

Deadline: Ongoing

The Clinical Microbiome

This joint Collection invites submissions of cutting-edge translational and clinical research, including microbiome-based diagnostics, therapeutics, interventions, and clinical trials.

Publishing Model: Hybrid

Deadline: Sep 11, 2025